title: Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.
abstract: Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.
authors.affiliation: Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.
authors.forename: Giada
authors.initials: G
authors.lastname: Bianchi
authors.affiliation: Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts. Irene_Ghobrial@dfci.harvard.edu.
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D007093:Imidazoles / Q000008:administration & dosage*; D007211:Indoles / Q000008:administration & dosage*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism*; D011804:Quinolines / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D006877:Hydroxamic Acids; D007093:Imidazoles; D007211:Indoles; D011804:Quinolines